Inify Laboratories - mandatory notification of trade

19 Dec 2025 08:37 CET

Stockholm, Sweden, December 19, 2025; Inify Laboratories AB (publ.) has been
notified that the following transactions have been completed by a primary
insider in Inify; Martin Ingvar, board member and primary insider in Inify, has
acquired 30,000 shares in Inify at an average price of NOK 3.30 per share on
December 18th. After the transaction, Ingvar holds 216,063 shares.

This information is subject to the disclosure requirements pursuant to the EU
Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the
Norwegian Securities Trading Act.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.

###

About Inify Laboratories

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)

More information:
Access the news on Oslo Bors NewsWeb site

662503_Mandatory_notification_of_trade_2025_12_19.pdf